Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMBRUVICA vs BRUKINSA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy,Waldenström's macroglobulinemia (WM) in adult patients,Relapsed or refractory marginal zone lymphoma (MZL) in adult patients who have received at least one prior anti-CD20-based regimen,Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients
560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.
320 mg orally once daily or 160 mg orally twice daily.
Terminal elimination half-life is approximately 4–6 hours. No clinically relevant accumulation is observed at steady state.
4 hours (terminal), supports twice-daily dosing
Ibrutinib is primarily metabolized by cytochrome P450 (CYP) 3A4, and to a minor extent by CYP2D6. The major active metabolite is PCI-45227, which has similar inhibitory activity against BTK. Avoid coadministration with strong or moderate CYP3A4 inhibitors or inducers.
Zanubrutinib is primarily metabolized by cytochrome P450 3A4 (CYP3A4). Following oral administration, it undergoes oxidation and further phase II metabolism. The major circulating metabolite is a product of CYP3A4-mediated oxidation.
Primarily via feces (approximately 80% as metabolites and parent drug); renal excretion accounts for <10% of the dose.
Biliary/fecal (87% as unchanged drug), renal (8% as unchanged drug)
Approximately 97.3% bound to plasma proteins (primarily albumin).
96% bound to plasma proteins (mainly albumin)
Volume of distribution is approximately 10,000 L (extremely large, indicating extensive tissue distribution, but not typically expressed in L/kg).
3.23 L/kg (central Vd), indicating extensive tissue distribution
Oral bioavailability is approximately 2.9% (low due to extensive first-pass metabolism and poor absorption; food increases exposure by about 60%).
Oral: 48% under fasting conditions; high-fat meal decreases AUC by 30%
No dose adjustment required for GFR ≥ 30 m L/min. For GFR < 30 m L/min, use with caution and monitor closely; no specific dose recommendation available.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 80 mg twice daily.
Child-Pugh A: 280 mg orally once daily (starting dose for CLL/SLL, WM, MZL, c GVHD) or 420 mg orally once daily (starting dose for MCL). Child-Pugh B: 140 mg orally once daily (CLL/SLL, WM, MZL, c GVHD) or 280 mg orally once daily (MCL). Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 80 mg twice daily. Child-Pugh C: not recommended.
Not approved for pediatric use. Safety and efficacy not established.
Safety and efficacy not established; no approved dosing.
No specific dose adjustment required; patients ≥65 years experienced higher incidence of certain adverse events (e.g., atrial fibrillation, hypertension) in clinical trials; monitor closely.
No specific dose adjustment; monitor for increased toxicity due to age-related renal/hepatic decline.
Hemorrhage: Fatal and serious hemorrhagic events have occurred in patients treated with IMBRUVICA. Major hemorrhage (≥ Grade 3) has occurred in up to 6% of patients. Bleeding events include intracranial hemorrhage, gastrointestinal bleeding, hematuria, and post-procedural hemorrhage. Monitor for signs of bleeding. Consider benefit-risk of surgery and the need for temporary interruption.
None
Hemorrhage: risk of bleeding, including fatal events; consider withholding for at least 3-7 days pre- and post-surgery,Infections: fatal and serious infections have occurred (e.g., pneumonia, sepsis); monitor for infections,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts,Cardiac arrhythmias: atrial fibrillation and ventricular tachyarrhythmias; monitor electrocardiogram and manage as appropriate,Tumor lysis syndrome: risk in patients with high tumor burden; ensure adequate hydration and monitoring,Hypertension: monitor blood pressure and initiate antihypertensive therapy as needed,Second primary malignancies: including skin cancers and other carcinomas,Hepatotoxicity: elevations in liver enzymes; monitor hepatic function,Embryo-fetal toxicity: can cause fetal harm; advise women of reproductive potential to avoid pregnancy
Hemorrhage: Serious and fatal hemorrhagic events may occur. Monitor for signs of bleeding. Consider benefit-risk in patients requiring antiplatelet or anticoagulant therapy.,Infections: Fatal and serious infections (including pneumonia, sepsis) have occurred. Monitor for signs of infection and manage promptly.,Cytopenias: Neutropenia, thrombocytopenia, and anemia may occur. Monitor blood counts regularly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for symptoms of arrhythmia and manage appropriately.,Second primary malignancies: Including non-melanoma skin cancer, have been reported. Advise patients to use sun protection.,Tumor lysis syndrome: Can occur. Assess risk and monitor patients appropriately.
None
None
Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos. These fruits inhibit CYP3A4 and increase ibrutinib levels, raising toxicity risk (bleeding, arrhythmias). No other significant food interactions.
Avoid grapefruit products and Seville oranges. No significant food effect on absorption; may be taken with or without food.
Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy unless benefit outweighs risk. For first trimester: high risk due to critical organogenesis; second and third trimesters: may cause fetal harm, including low birth weight and developmental abnormalities.
Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of zanubrutinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity including increased post-implantation loss, reduced fetal body weights, and increased incidence of skeletal variations at exposures less than or equal to human clinical exposure at the recommended dose of 320 mg daily. Therefore, avoid use during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. If used, advise pregnant women of the potential risk to the fetus.
No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 1 week after last dose. M/P ratio unknown.
There are no data on the presence of zanubrutinib in human milk, effects on the breastfed child, or effects on milk production. Zanubrutinib and its metabolites are excreted in the milk of lactating rats with concentrations approximately 2 times higher than maternal plasma (M/P ratio approximately 2). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with BRUKINSA and for at least 2 weeks after the last dose.
No specific dose adjustments established. Consider alternative therapy if pregnancy occurs. Systemic exposure may decrease due to increased plasma volume and hepatic metabolism, but no PK data in pregnancy. Do not adjust dose; discontinue if pregnancy occurs unless benefit justifies risk.
No specific dose adjustments are recommended for BRUKINSA during pregnancy due to lack of pharmacokinetic data in pregnant women. However, pregnancy-induced physiological changes (e.g., increased plasma volume, altered hepatic metabolism) may affect drug concentrations. Standard dosing (320 mg once daily or 160 mg twice daily) is used if treatment is deemed necessary, with close monitoring for efficacy and toxicity. There are no pregnancy-specific pharmacokinetic studies to guide dose modification.
Monitor for atrial fibrillation (ECG if palpitations), bleeding risk due to antiplatelet effect (hold 3-7 days before surgery), and tumor lysis syndrome (especially CLL with high lymphocytosis). CYP3A4 substrate: avoid strong inhibitors (ketoconazole, clarithromycin) and reduce dose with moderate inhibitors (fluconazole, diltiazem). Check for HBV reactivation before starting.
Monitor for atrial fibrillation/flutter and hemorrhage; baseline ECG recommended. Dose adjust for severe hepatic impairment (Child-Pugh C). Avoid strong or moderate CYP3A inhibitors/inducers; use with caution in patients requiring antiplatelet or anticoagulant therapy.
Take with a full glass of water at the same time each day. Swallow capsules whole, do not open, break, or chew.,Do not drink grapefruit juice, Seville oranges, or pomelos while taking this medication.,Report any new or worsening bruising, bleeding, black/tarry stools, or pink/dark urine immediately.,Seek medical attention for symptoms of atrial fibrillation like palpitations, chest discomfort, or shortness of breath.,Avoid activities that increase bleeding risk (e.g., contact sports) until you know how the drug affects you.,Inform all healthcare providers (including dentists) that you are taking ibrutinib before any procedures.
Take BRUKINSA with or without food, but avoid grapefruit and Seville oranges.,Swallow capsules whole; do not crush or chew.,Inform your doctor of any bleeding or bruising, irregular heartbeat, or signs of infection.,Do not use antacids, proton pump inhibitors, or histamine-2 blockers without consulting your doctor.,If you miss a dose, take it as soon as remembered unless it is less than 12 hours until the next dose; then skip the missed dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMBRUVICA vs BRUKINSA, answered by our medical review team.
IMBRUVICA is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.. BRUKINSA is a Antineoplastic BTK Inhibitor that works by Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMBRUVICA and BRUKINSA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMBRUVICA is: 560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.. The standard adult dose of BRUKINSA is: 320 mg orally once daily or 160 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMBRUVICA and BRUKINSA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMBRUVICA is classified as Category C. Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy . BRUKINSA is classified as Category C. Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.